person · Reporting owner

SAUNDERS BRENT L

Disclosed activity across 7 companies

Tapewire entity: 11572
SEC CIK: 0001268854

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SPRY · Entity 883	Director	June 24, 2026	June 26, 2026
Bausch & Lomb CorpBLCO · Entity 3756	Director · Chairman of the Board and CEO	August 05, 2026	August 07, 2026
BridgeBio Pharma, Inc.BBIO · Entity 3360	Director	June 22, 2022	June 24, 2022
CISCO SYSTEMS, INC.CSCO · Entity 2802	Director	December 08, 2022	December 12, 2022
SkinHealth Systems Inc.SKIN · Entity 6863	Director · Chairman	June 16, 2025	June 18, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23	Direct	30,000	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Bausch & Lomb Corp

Report date August 05, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	1,256,037	Ending reported balance After 2026-08-05 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-05 · Tax withholding · Disposed 4,231 · Balance 974,158 F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Row 2 · 2026-08-05 · Grant · Acquired 281,879 · Balance 1,256,037 F2: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units.

F2: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.

BridgeBio Pharma, Inc.

Report date June 22, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2032-06-22	Direct	104,921	Reported balance After 2022-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-22 · Grant · Acquired 104,921 · Balance 104,921 F1: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

CISCO SYSTEMS, INC.

Report date December 08, 2022 · Filed December 12, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,143	Reported balance After 2022-12-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-12-08 · Grant · Acquired 5,001 · Balance 24,143 F1: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code. F2: Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock. F3: Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2: Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

F3: Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person.

SkinHealth Systems Inc.

Report date June 16, 2025 · Filed June 18, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	5,994,820	Reported balance After 2025-06-16 transaction · row 1 1 source row Row 1 · 2025-06-16 · Grant · Acquired 73,051 · Balance 5,994,820 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.
Class A Common StockSEC Table I · non-derivative	IndirectBy Triplet	1,681,771	Reported balance Holding disclosure · report date 2025-06-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,681,771 F2: Represents securities held by Triplet Enterprises III, LLC ("Triplet"). The reporting person is the managing member of Triplet and may be deemed to beneficially own the securities held by Triplet, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Trust	1,121,180	Reported balance Holding disclosure · report date 2025-06-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,121,180 F3: Represents securities held by the Saunders Family Trust ("Trust"). The reporting person has voting and dispositive control over these securities and thus the reporting person may be deemed to beneficially own the securities held by Trust, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.

F2: Represents securities held by Triplet Enterprises III, LLC ("Triplet"). The reporting person is the managing member of Triplet and may be deemed to beneficially own the securities held by Triplet, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

F3: Represents securities held by the Saunders Family Trust ("Trust"). The reporting person has voting and dispositive control over these securities and thus the reporting person may be deemed to beneficially own the securities held by Trust, but disclaims beneficial ownership of such securities except to any pecuniary interest the reporting person may have therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 149,384.28 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-05-08 · Disposition to issuer · Disposed 79,805 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $224.00 · Expires 2023-05-08	Direct	Reported balance After 2020-05-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-08 · Disposition to issuer · Disposed 104,651 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $91.13 · Expires 2023-09-30	Direct	Reported balance After 2020-05-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-05-08 · Disposition to issuer · Disposed 3,291 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-08 · Disposition to issuer · Disposed 1,018 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2021-08-22	Direct	Reported balance After 2020-05-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-05-08 · Disposition to issuer · Disposed 9,446 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $73.14 · Expires 2022-08-22	Direct	Reported balance After 2020-05-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-05-08 · Disposition to issuer · Disposed 3,691 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $90.22 · Expires 2023-08-14	Direct	Reported balance After 2020-05-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-05-08 · Disposition to issuer · Disposed 2,790 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $91.13 · Expires 2023-09-30	Direct	Reported balance After 2020-05-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-05-08 · Disposition to issuer · Disposed 219,667 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-05-08 · Disposition to issuer · Disposed 62,547 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2024-05-12	Direct	Reported balance After 2020-05-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-05-08 · Disposition to issuer · Disposed 1 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-05-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-05-08 · Disposition to issuer · Disposed 83,936 · Balance 0 F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.

F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Merck & Co., Inc.

Report date November 03, 2009 · Filed November 04, 2009

Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Not disclosed	Reported balance After 2009-11-03 transaction · row 1 1 source row Row 1 · 2009-11-03 · Disposition to issuer · Disposed 50,783 · Balance Not disclosed F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18	Direct	0	Reported balance After 2009-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2009-11-03 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.27 · Expires 2013-10-31	Direct	0	Reported balance After 2009-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-11-03 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2009-11-03 · Disposition to issuer · Disposed 140,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24	Direct	0	Reported balance After 2009-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2009-11-03 · Disposition to issuer · Disposed 130,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2009-11-03 · Disposition to issuer · Disposed 130,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30	Direct	0	Reported balance After 2009-11-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2009-11-03 · Disposition to issuer · Disposed 130,100 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22	Direct	0	Reported balance After 2009-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2009-11-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.
Phantom Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2009-11-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2009-11-03 · Disposition to issuer · Disposed 65,587.15 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.

F2: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F4: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 05, 2026 Filed Aug 7, 2026 20:30 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	281,879	$0.00	$0.00	Disclosure SEC source: 0001860742-26-000089 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman of the Board and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,256,037 F2 · shares: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date. Read SEC document
August 05, 2026 Filed Aug 7, 2026 20:30 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	4,231	$16.76	$70,911.56	Disclosure SEC source: 0001860742-26-000089 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman of the Board and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 974,158 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $10.54	$0.00	Disclosure SEC source: 0001268854-26-000002 · form4-06262026_040607.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
May 22, 2026 Filed May 26, 2026 20:56 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	2,886	$15.92	$45,945.12	Disclosure SEC source: 0001860742-26-000071 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman of the Board and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 978,389 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:32 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	14,700	$0.00	$0.00	Disclosure SEC source: 0001860742-26-000054 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 981,275 F2 · shares: Represents matching restricted share units ("MRSUs") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances). Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:32 UTC	Bausch & Lomb Corp BLCO · Entity 3756	PurchaseCommon Shares, No Par Value	14,700	$17.14	$251,958.00	Disclosure SEC source: 0001860742-26-000054 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 966,575 F1 · price: Reflects a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.09 to $17.19 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
February 27, 2026 Filed Mar 2, 2026 22:44 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	24,649	$18.30	$451,076.70	Disclosure SEC source: 0001860742-26-000041 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951,875 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
February 26, 2026 Filed Mar 2, 2026 22:44 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	22,059	$18.49	$407,870.91	Disclosure SEC source: 0001860742-26-000041 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,524 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:03 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	327,102	$0.00	$0.00	Disclosure SEC source: 0001860742-26-000028 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 998,583 F1 · shares: Reflects the grant of restricted share units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document
February 23, 2026 Filed Feb 25, 2026 21:58 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	65,444	$17.99	$1,177,337.56	Disclosure SEC source: 0001860742-26-000027 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671,481 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
August 05, 2025 Filed Aug 7, 2025 20:23 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	4,231	$14.44	$61,095.64	Disclosure SEC source: 0001127602-25-020237 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 736,925 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
July 21, 2025 Filed Jul 23, 2025 21:35 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantPerformance Stock Units · Derivative	150,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-097980 · ownership.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Shares, No Par Value · 900,000 shares Expires not disclosed F1 · derivative.exercise_price: Reflects an amendment on July 21, 2025 (the "Amendment") to an award of performance stock units ("PSUs") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") on February 23, 2023 (the "New Hire PSUs"). Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan. F2 · derivative.exercise_price: Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the "Measurement End Date") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date. F3 · derivative.exercise_price: The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment. F1 · derivative.exercise_date: Reflects an amendment on July 21, 2025 (the "Amendment") to an award of performance stock units ("PSUs") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") on February 23, 2023 (the "New Hire PSUs"). Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan. F2 · derivative.exercise_date: Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the "Measurement End Date") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date. F3 · derivative.exercise_date: The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment. F1 · derivative.expiration_date: Reflects an amendment on July 21, 2025 (the "Amendment") to an award of performance stock units ("PSUs") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") on February 23, 2023 (the "New Hire PSUs"). Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan. F2 · derivative.expiration_date: Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the "Measurement End Date") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date. F3 · derivative.expiration_date: The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment. F1 · derivative.underlying_shares: Reflects an amendment on July 21, 2025 (the "Amendment") to an award of performance stock units ("PSUs") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") on February 23, 2023 (the "New Hire PSUs"). Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan. F2 · derivative.underlying_shares: Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the "Measurement End Date") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date. F3 · derivative.underlying_shares: The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment. F1 · balance_after: Reflects an amendment on July 21, 2025 (the "Amendment") to an award of performance stock units ("PSUs") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") on February 23, 2023 (the "New Hire PSUs"). Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan. F2 · balance_after: Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the "Measurement End Date") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date. F3 · balance_after: The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment. Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:30 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $17.26	$0.00	Disclosure SEC source: 0001415889-25-018384 · form4-06272025_040607.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:34 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	73,051	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-032141 · wk-form4_1750278831.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,994,820 F1 · kind: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F1 · price: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F1 · acquired: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. Read SEC document
May 22, 2025 Filed May 27, 2025 12:16 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	22,000	$0.00	$0.00	Disclosure SEC source: 0001127602-25-015582 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,156 F2 · shares: Represents matching restricted share units ("MRSUs") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances). Read SEC document
May 22, 2025 Filed May 27, 2025 12:16 UTC	Bausch & Lomb Corp BLCO · Entity 3756	PurchaseCommon Shares, No Par Value	22,000	$11.28	$248,072.00	Disclosure SEC source: 0001127602-25-015582 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,156 F1 · shares: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.19 to $11.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
May 20, 2025 Filed May 22, 2025 21:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	Exercise / conversionStock Option (Right to Buy) · Derivative	120,000	$0.00 Strike: $1.01	$0.00	Disclosure SEC source: 0001415889-25-014185 · form4-05222025_050503.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,950 Underlying: Common Stock · 120,000 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document
May 20, 2025 Filed May 22, 2025 21:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	SaleCommon Stock	120,000	$14.25	$1,710,024.00	Disclosure SEC source: 0001415889-25-014185 · form4-05222025_050503.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
May 20, 2025 Filed May 22, 2025 21:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	Exercise / conversionCommon Stock	120,000	$1.01	$121,200.00	Disclosure SEC source: 0001415889-25-014185 · form4-05222025_050503.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2025 Filed Feb 28, 2025 21:23 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantNon-Qualified Stock Options (right to purchase) · Derivative	600,858	$0.00 Strike: $15.86	$0.00	Disclosure SEC source: 0001127602-25-007260 · form4.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,858 Underlying: Common Shares, No Par Value · 600,858 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase common shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document
February 26, 2025 Filed Feb 28, 2025 21:23 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	168,168	$0.00	$0.00	Disclosure SEC source: 0001127602-25-007260 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,156 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document
December 23, 2024 Filed Dec 26, 2024 21:18 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	24,649	$17.83	$439,491.67	Disclosure SEC source: 0001127602-24-030056 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,988 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
December 23, 2024 Filed Dec 26, 2024 21:18 UTC	Bausch & Lomb Corp BLCO · Entity 3756	Tax withholdingCommon Shares, No Par Value	73,782	$17.83	$1,315,533.06	Disclosure SEC source: 0001127602-24-030056 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,637 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document
August 12, 2024 Filed Aug 13, 2024 21:00 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	PurchaseClass A Common Stock	40,450	$1.08	$43,686.00	Disclosure SEC source: 0001628280-24-036967 · wk-form4_1723582804.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,921,769 Read SEC document
August 05, 2024 Filed Aug 7, 2024 21:29 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	32,250	$0.00	$0.00	Disclosure SEC source: 0001127602-24-021823 · form4.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,419 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares reported on Table I above, pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document
August 05, 2024 Filed Aug 7, 2024 21:29 UTC	Bausch & Lomb Corp BLCO · Entity 3756	PurchaseCommon Shares, No Par Value	32,250	$15.66	$505,067.25	Disclosure SEC source: 0001127602-24-021823 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,169 F1 · shares: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.395 to $15.8 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
July 08, 2024 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	78,534	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 6 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,881,319 F2 · kind: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F2 · price: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F2 · acquired: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. Read SEC document
June 20, 2024 Filed Jun 24, 2024 21:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $7.73	$0.00	Disclosure SEC source: 0001415889-24-018010 · form4-06242024_050602.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:26 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantNon-Qualified Stock Options (right to purchase) · Derivative	569,105	$0.00 Strike: $16.85	$0.00	Disclosure SEC source: 0001127602-24-007883 · form4.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,105 Underlying: Common Shares, No Par Value · 569,105 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase common shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:26 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	187,919	$0.00	$0.00	Disclosure SEC source: 0001127602-24-007883 · form4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,919 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document
August 16, 2023 Filed Aug 17, 2023 21:11 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	PurchaseClass A Common Stock	59,380	$6.10	$362,372.39	Disclosure SEC source: 0001628280-23-029854 · wk-form4_1692306684.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,827,453 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.04 to $6.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 27, 2023 Filed Jun 29, 2023 01:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $6.50	$0.00	Disclosure SEC source: 0001209191-23-040109 · doc4.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:16 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	16,357	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-022509 · wk-form4_1686950173.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,768,073 F1 · kind: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F1 · price: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. F1 · acquired: Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time. Read SEC document
February 03, 2023 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	13,548	$12.90	$174,769.20	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 5 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,802,785 F1 · kind: Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale. Read SEC document
December 30, 2022 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	2,167	$9.10	$19,719.70	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 4 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,816,333 F1 · kind: Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale. Read SEC document
December 08, 2022 Filed Dec 12, 2022 23:43 UTC	CISCO SYSTEMS, INC. CSCO · Entity 2802	GrantCommon Stock	5,001	$0.00	$0.00	Disclosure SEC source: 0001209191-22-060763 · doc4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,143 F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code. F2 · balance_after: Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock. F3 · balance_after: Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person. Read SEC document
November 08, 2022 Filed Nov 10, 2022 23:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock option (right to buy) · Derivative	153,647	Not disclosed Strike: $1.01	Not disclosed	Disclosure SEC source: 0001209191-22-056441 · doc4.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,647 Underlying: Common Stock · 153,647 shares Expires 2031-06-15 F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F4 · price: Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS with the exercise price of $1.19 per share pursuant to the Merger Agreement. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document
November 08, 2022 Filed Nov 10, 2022 23:00 UTC	ARS Pharmaceuticals, Inc. SPRY · Entity 883	GrantStock option (right to buy) · Derivative	590,950	Not disclosed Strike: $1.01	Not disclosed	Disclosure SEC source: 0001209191-22-056441 · doc4.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,950 Underlying: Common Stock · 590,950 shares Expires 2031-06-15 F2 · price: Received in exchange for a stock option to acquire 500,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.19 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document
September 30, 2022 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	2,166	$11.79	$25,537.14	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,818,500 F1 · kind: Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale. Read SEC document
June 30, 2022 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	3,076	$12.86	$39,557.36	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820,666 F1 · kind: Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:35 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	104,921	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0001209191-22-039264 · doc4.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
March 31, 2022 Filed Jul 10, 2024 20:32 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	3,711	$16.88	$62,641.68	Disclosure SEC source: 0001628280-24-031586 · wk-form4_1720643557.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,823,742 F1 · kind: Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale. Read SEC document
February 04, 2022 Filed Feb 9, 2022 01:16 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	158,450	Not disclosed	Not disclosed	Disclosure SEC source: 0001818093-22-000031 · wf-form4_164436938991494.xml · nonDerivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751,716 F2 · kind: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. F2 · price: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. Read SEC document
February 04, 2022 Filed Feb 9, 2022 01:16 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	35,581	Not disclosed	Not disclosed	Disclosure SEC source: 0001818093-22-000031 · wf-form4_164436938991494.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,593,266 F1 · kind: Represents a grant of restricted stock units that vest in 25% increments on each of March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. F1 · price: Represents a grant of restricted stock units that vest in 25% increments on each of March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. Read SEC document
January 27, 2022 Filed Jan 31, 2022 17:31 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	Tax withholdingClass A Common Stock	6,812	$12.24	$83,378.88	Disclosure SEC source: 0001818093-22-000021 · wf-form4_164365026176711.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,557,685 F1 · shares: On December 31, 2021, 30,963 restricted stock units vested in full. All of the shares reported as disposed of in this Form 4 represents the number of shares of Class A Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale. Read SEC document
December 29, 2021 Filed Jan 4, 2022 00:59 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	PurchaseCommon Stock	17,600	$14.48	$254,879.68	Disclosure SEC source: 0000899243-22-000193 · doc4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 F1 · price: Represents the weighted average purchase price of the shares purchased from $14.45 to $14.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote. Read SEC document
December 13, 2021 Filed Dec 16, 2021 01:07 UTC	CISCO SYSTEMS, INC. CSCO · Entity 2802	GrantCommon Stock	4,180	$0.00	$0.00	Disclosure SEC source: 0001209191-21-069855 · doc4.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,503 F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code. F2 · balance_after: Includes 2,344 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock. Read SEC document
September 10, 2021 Filed Sep 14, 2021 23:53 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantPerformance Restricted Stock Units · Derivative	60,000	$0.00	$0.00	Disclosure SEC source: 0001818093-21-000067 · wf-form4_163166358942566.xml · derivative · entry 4 SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Stock · 60,000 shares Expires not disclosed F4 · derivative.exercise_price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F4 · price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F4 · derivative.exercise_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F4 · derivative.expiration_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. Read SEC document
September 10, 2021 Filed Sep 14, 2021 23:53 UTC	SkinHealth Systems Inc. SKIN · Entity 6863	GrantClass A Common Stock	30,963	$0.00	$0.00	Disclosure SEC source: 0001818093-21-000067 · wf-form4_163166358942566.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,564,497 F1 · price: Represents restricted stock units (the "RSUs") granted in lieu of annual cash salary and bonus for 2021. The RSUs will vest in full on December 31, 2021, subject to continued service with the Company. Read SEC document
June 17, 2021 Filed Jun 22, 2021 23:08 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	38,895	$0.00 Strike: $62.63	$0.00	Disclosure SEC source: 0000899243-21-025387 · doc4.xml · derivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.